Skip to main content

Table 3 Comparison of dosimetric characteristics

From: Dosimetric comparison between VMAT plans using the fast-rotating O-ring linac with dual-layer stacked MLC and helical tomotherapy for nasopharyngeal carcinoma

Parameters

HT

HL2arc

HL4arc

Pa

Median (IQR)

HT vs. HL2arc

HT vs. HL4arc

HL2arc vs. HL4arc

P_GTV

D2 (Gy)

69.6 (69.30, 70.03)

70.86 (70.13, 71.60)

70.41 (69.63, 70.85)

0.00

0.01

0.00

D98 (Gy)

66.67 (66.51, 66.75)

66.45 (66.37, 66.61)

66.52 (66.41, 66.77)

0.02

0.59

0.15

HI

1.04 (1.03, 1.05)

1.06 (1.05, 1.08)

1.06 (1.04, 1.06)

0.00

0.00

0.00

CI

0.80 (0.76, 0.83)

0.79 (0.74, 0.84)

0.83 (0.79, 0.87)

0.56

0.11

0.00

P_CTV

D2 (Gy)

69.13 (68.61, 69.48)

69.89 (69.54, 71.14)

69.67 (69.09, 70.24)

0.00

0.00

0.00

D98 (Gy)

55.32 (54.97, 55.69)

55.04 (54.53, 55.85)

55.17 (54.60, 55.68)

0.29

0.98

> 0.99

HI

1.25 (1.24, 1.26)

1.28 (1.26, 1.29)

1.27 (1.25, 1.28)

0.00

0.01

0.00

CI

0.80 (0.78, 0.82)

0.83 (0.79, 0.88)

0.88 (0.85, 0.89)

0.03

0.00

0.00

Brain stem

Dmax (Gy)

46.99 (39.98, 53.64)

39.29 (34.42, 48.36)

39.49 (31.92, 45.92)

0.00

0.00

0.33

p_cord

Dmax (Gy)

39.91 (31.19, 43.46)

33.38 (29.75, 44.01)

28.32 (25.20, 34.19)

> 0.99

0.00

0.00

Parotid glands

Dmean (Gy)

25.88 (23.87, 27.87)

28.00 (23.24, 33.99)

25.36 (22.22, 26.89)

0.04

0.05

0.00

Esophagus

Dmean (Gy)

2.00 (0.68, 4.20)

2.97 (0.89, 7.55)

3.38 (1.01, 6.79)

0.00

0.00

> 0.99

Optic chiasm

Dmax (Gy)

9.58 (5.95, 24.87)

6.07 (4.96, 18.89)

6.22 (4.92, 15.28)

0.00

0.00

0.05

Optic nerve

Dmax (Gy)

14.03 (7.02, 27.02)

7.85 (5.55, 17.15)

7.47 (5.46, 14.65)

0.00

0.00

0.08

Cochlea

Dmean (Gy)

26.05 (22.69, 30.10)

32.97 (29.01, 38.71)

37.40 (33.49, 40.65)

0.00

0.00

0.02

Eyeball

Dmax (Gy)

14.14 (9.60, 17.42)

11.31 (5.09, 17.74)

10.90 (5.36, 17.50)

0.76

0.14

0.26

Lens

Dmax (Gy)

2.66 (1.94, 3.95)

3.07 (2.12, 6.05)

3.03 (2.11, 5.36)

0.01

0.00

> 0.99

Oral cavity

Dmean (Gy)

22.03 (19.79, 24.85)

23.96 (20.84, 28.02)

24.14 (20.17, 27.53)

0.03

0.04

> 0.99

V15 (%)

63.57 (56.46, 75.79)

86.46 (68.99, 93.65)

82.62 (60.65, 97.29)

0.01

0.00

0.66

V30 (%)

22.09 (17.03, 29.39)

26.14 (16.58, 38.12)

22.41 (16.04, 32.76)

0.29

> 0.99

0.31

V45 (%)

6.29 (4.34, 9.73)

5.53 (3.04, 9.33)

6.01 (3.08, 8.30)

0.87

0.01

0.71

SMG

Dmean (Gy)

23.49 (21.56, 25.07)

24.01 (22.96, 26.28)

24.17 (22.49, 25.30)

0.02

0.11

0.66

Dose spillage volume

VHS for P_GTV

1.68 (1.35, 2.12)

2.03 (1.40, 3.01)

1.81 (1.22, 2.64)

0.01

> 0.99

0.00

VHS for P_CTV

0.61 (0.56, 0.71)

0.43 (0.39, 0.55)

0.40 (0.36, 0.42)

0.00

0.00

0.00

VIS for P_CTV

3.75 (3.40, 4.24)

2.79 (2.56, 3.10)

2.62 (2.46, 2.85)

0.00

0.00

0.03

VLS for P_CTV

13.02 (11.02, 13.95)

6.14 (5.87, 6.61)

6.00 (5.67, 6.58)

0.00

0.00

0.15

  1. HT, helical tomotherapy; HL2arc, halcyon two arc; HL4arc, halcyon four arc; P-GTV, planning gross target volume; P-CTV, planning clinical target volume; P-cord, planning spinal cord; SMG, submandibular glans; DV, D dose delivered to V% of organ volume; VD, percentage of organ volume receiving D Gy or higher; Dmax, maximum dose; Dmean, mean dose; CI, dose conformity index; HI, dose homogeneity index; VHS, high dose-spillage volume; VIS, intermediate dose-spillage volume; VLS, low dose-spillage volume; IQR, interquartile range (Q1, Q3)
  2. aThe Wilcoxon signed rank test was used by the Bonferroni correction for multiple testing